[Hidradenitis suppurativa]

Area of Science:

• Dermatology
• Immunology
• Internal Medicine

Background:

• Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant treatment challenges.
• HS is frequently associated with comorbidities like metabolic syndrome and psychiatric disorders.
• Diagnostic delays are common, leading to prolonged treatment histories before effective therapies are initiated.

Purpose of the Study:

• To review recent literature on hidradenitis suppurativa (HS).
• To summarize current treatment strategies, associated comorbidities, and diagnostic challenges in HS.
• To highlight the evolving landscape of biologic therapies for HS.

Main Methods:

• Comprehensive literature review of recent publications on HS.
• Analysis of data regarding treatment outcomes, comorbidities, and diagnostic timelines.
• Examination of approved and investigational biologic therapies for HS.

Main Results:

• HS management remains complex due to its chronic inflammatory nature.
• Significant diagnostic delays contribute to extensive prior treatment regimens.
• Several biologic therapies, including adalimumab, secukinumab, and bimekizumab, are approved for moderate to severe HS by the EMA.
• Numerous promising biologics are under investigation for moderate to severe HS.

Conclusions:

• Effective management of HS requires addressing its chronic inflammatory nature and associated comorbidities.
• Reducing diagnostic delay is critical for timely and appropriate treatment initiation.
• The development of novel biologic therapies offers significant hope for improved outcomes in moderate to severe HS patients.